Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
作者信息
Troya Jesús, Ryan Pablo, Ribera Esteban, Podzamczer Daniel, Hontañón Victor, Terrón Jose Alberto, Boix Vicente, Moreno Santiago, Barrufet Pilar, Castaño Manuel, Carrero Ana, Galindo María José, Suárez-Lozano Ignacio, Knobel Hernando, Raffo Miguel, Solís Javier, Yllescas María, Esteban Herminia, González-García Juan, Berenguer Juan, Imaz Arkaitz
出版信息
PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0164455.].
摘要
相似文献
1
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.
2
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全的治疗策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016.
3
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.阿巴卡韦/拉米夫定+利匹韦林方案治疗初治HIV-1感染患者的有效性和安全性
J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. doi: 10.1093/jac/dkw347. Epub 2016 Sep 2.
4
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.利匹韦林联合阿巴卡韦和拉米夫定用于病毒载量不可测的HIV-1感染患者的长期疗效和安全性
PLoS One. 2018 Feb 16;13(2):e0191300. doi: 10.1371/journal.pone.0191300. eCollection 2018.
5
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.替诺福韦艾拉酚胺/恩曲他滨与阿巴卡韦/拉米夫定用于治疗病毒学抑制的 HIV-1 感染成人：一项随机、双盲、活性对照、非劣效性 3 期试验。
Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20.
6
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.在接受高效抗逆转录病毒治疗（HAART）且病毒学抑制的HIV感染患者中换用阿巴卡韦/拉米夫定（ABC/3TC）加rilpivirine（RPV）的疗效和安全性。
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):815-9. doi: 10.1007/s10096-016-2602-3. Epub 2016 Feb 15.
7
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.阿巴卡韦/拉米夫定/齐多夫定与依非韦伦每日一次简化疗法治疗HIV-1感染的初步研究。
HIV Clin Trials. 2006 Sep-Oct;7(5):229-36. doi: 10.1310/hct0705-229.
8
Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.在常规临床实践中，使用未增强的阿扎那韦联合复方拉米夫定/阿巴卡韦作为一种简化的不含利托那韦的治疗策略。
HIV Clin Trials. 2009 May-Jun;10(3):129-34. doi: 10.1310/hct1003-129.
9
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
PLoS One. 2016 Jul 8;11(7):e0159286. doi: 10.1371/journal.pone.0159286. eCollection 2016.
10
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.将齐多夫定/阿巴卡韦/拉米夫定治疗的脂肪萎缩患者转换为洛匹那韦/利托那韦加或不加阿巴卡韦/拉米夫定治疗。
J Antimicrob Chemother. 2013 Jun;68(6):1373-81. doi: 10.1093/jac/dks540. Epub 2013 Feb 5.
本文引用的文献
1
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.阿巴卡韦/拉米夫定联合rilpivirine是HIV-1抑制患者的有效且安全的治疗策略：SIMRIKI回顾性研究的48周结果
PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016.
Zotero 插件